Finerenone in Non-Diabetic Proteinuria
Current evidence does not support routine use of finerenone in non-diabetic CKD with proteinuria, as the KDIGO 2024 guidelines explicitly recommend nonsteroidal MRAs only for adults with type 2 diabetes and CKD. However, emerging trial data from FIND-CKD suggests potential benefit, creating a gap between guideline recommendations and recent evidence.
Current Guideline Position
The KDIGO 2024 guidelines are clear: finerenone is suggested only for adults with T2D, eGFR >25 ml/min/1.73 m², normal potassium, and albuminuria >30 mg/g despite maximum tolerated RAS inhibitor 1. The guidelines do not extend this recommendation to non-diabetic CKD patients, as the evidence base at the time of publication was limited to diabetic populations.
Key Limitation
The guideline recommendation (3.8.1) carries a 2A grade and explicitly states it applies to "adults with T2D" 1. No parallel recommendation exists for non-diabetic proteinuric CKD in the 2024 KDIGO guidelines.
Emerging Evidence from FIND-CKD Trial
The landscape changed with publication of FIND-CKD (2026), which demonstrated that finerenone slowed eGFR decline by 0.7 ml/min/1.73 m² per year compared to placebo in non-diabetic CKD patients (P<0.001) 2. This trial enrolled 1,584 adults without diabetes who had:
- eGFR 25 to <90 ml/min/1.73 m²
- UACR 200 to ≤3,500 mg/g
- Already receiving a RAS inhibitor
The trial showed a 23% relative risk reduction in the composite kidney/cardiovascular outcome (HR 0.77,95% CI 0.60-0.99) 2. Most participants had chronic glomerulonephritis (57.0%), with IgA nephropathy being the most common specific diagnosis (26.3%) 3.
Clinical Decision Algorithm
If You Choose to Use Finerenone Off-Guideline (Based on FIND-CKD):
Patient Selection Criteria:
- Non-diabetic CKD with eGFR 25-90 ml/min/1.73 m²
- UACR ≥200 mg/g (preferably ≥500 mg/g for stronger indication)
- Already on maximum tolerated ACE inhibitor or ARB
- Baseline potassium ≤4.8 mmol/L (≤4.8 mEq/L)
Initiation Dosing (per KDIGO algorithm) 1:
| Baseline K+ | eGFR | Starting Dose |
|---|---|---|
| ≤4.8 mmol/L | 25-59 ml/min/1.73 m² | 10 mg daily |
| ≤4.8 mmol/L | ≥60 ml/min/1.73 m² | 20 mg daily |
| 4.9-5.5 mmol/L | Any | Do not initiate |
| >5.5 mmol/L | Any | Contraindicated |
Monitoring Protocol 1:
At 1 month after initiation:
- Check potassium, creatinine, eGFR
- If K+ ≤4.8 mmol/L and started on 10 mg: increase to 20 mg daily
- If K+ 4.9-5.5 mmol/L: continue current dose, recheck in 2 weeks
- If K+ >5.5 mmol/L: hold finerenone, address hyperkalemia
Every 4 months thereafter:
- Monitor potassium, creatinine, eGFR
- Continue if K+ ≤5.5 mmol/L
- Hold if K+ >5.5 mmol/L
Managing Hyperkalemia:
- K+ 4.9-5.5 mmol/L: Continue finerenone, monitor more frequently
- K+ >5.5 mmol/L: Hold finerenone, adjust diet/medications, recheck K+
- Restart at 10 mg daily when K+ ≤5.0 mmol/L 1
Real-World Safety Data
In FIND-CKD, hyperkalemia occurred in 17.0% with finerenone vs 13.3% with placebo, but led to discontinuation in only 1.5% vs 0.1% and hospitalization in 0.9% vs 0.6% 2. A Chinese real-world study showed similar safety with minimal eGFR impact and effective proteinuria reduction 4.
Combination with SGLT2 Inhibitors
Finerenone can be added to SGLT2 inhibitors in non-diabetic CKD 5. A small randomized trial (n=20) demonstrated additive albuminuria reduction when combining dapagliflozin and finerenone, with a 36% overall UACR reduction and acceptable safety profile 5. This mirrors the diabetic CKD data where combination therapy is explicitly mentioned as appropriate 1.
Critical Caveats
This represents off-guideline use. The KDIGO 2024 guidelines do not recommend finerenone for non-diabetic CKD because they were published before FIND-CKD results. The trial data is compelling but represents a single phase 3 study 2.
Glomerular disease subgroup: In patients with glomerular diseases (IgA nephropathy, FSGS, membranous nephropathy), finerenone showed consistent benefit with 0.73 ml/min/1.73 m² per year slower eGFR decline and 42% albuminuria reduction 6.
Expect transient eGFR decline: Real-world data shows initial eGFR dip at 3 months (88.3→82.1 ml/min/1.73 m²) with recovery by 6 months (87.1 ml/min/1.73 m²) 4, similar to RAS inhibitor initiation patterns.
Practical Recommendation
For non-diabetic proteinuric CKD patients already optimized on RAS inhibitors with persistent albuminuria ≥200 mg/g, finerenone represents a reasonable evidence-based option based on FIND-CKD trial data 2, though it remains off-guideline until KDIGO updates its recommendations. Use the dosing and monitoring algorithm above, with particular attention to potassium management. The combination with SGLT2 inhibitors appears safe and potentially additive for proteinuria reduction 5.